
ECL · NYSE
Expected to report Feb 9, 2027 — estimated from last year’s reporting date.
Consensus is $2.19 EPS for Dec 2026 across 8 estimates, ranging $2.18 to $2.21.
Ecolab’s third quarter showed the sales and operating acceleration management had flagged as an inflection point. Revenue of $4.695 billion rose 13% year over year from $4.165 billion and about 6% sequentially from $4.42 billion in Q2. Organic growth accelerated to 7%, driven by 5% pricing and 2% volume. Adjusted diluted EPS of $2.18 met consensus, increased 5% from $2.07 a year ago and rose from $2.09 in Q2. Reported EPS was $1.95, down 5% year over year, reflecting special charges and higher acquisition-related costs.
The defining feature was the combination of broader core-business improvement and exceptional growth in newer platforms. Organic operating income grew 11%, with organic operating margin expanding 70 basis points to 19.6%; organic gross margin was essentially stable at 44.9% despite higher commodities. Global High-Tech grew 63% organically and Life Sciences 17%, while Food & Beverage accelerated and Heavy Water and Paper returned to growth. Ovivo and CoolIT helped lift reported sales but also brought higher amortization and financing costs: net interest expense rose to $124.8 million from $55.3 million, and management estimated a 10% headwind to adjusted EPS growth. Ecolab maintained its 2026 adjusted EPS outlook of $8.10-$8.20 and sees further growth and margin progress in 2027.